Anal cancer is a rare type of cancer in the anal canal. The anal canal is a short tube, about 1-1½ inches long between anal opening and rectum through which stool passes out of the human body. Some of the symptoms associated with anal cancer include anal or rectum bleeding, lump near anus, pain around the anus, itching in the anus, discharge from the anus, changes in bowel habits, and others. Anal cancer can be caused due to a number of risk factors such as human papillomavirus (HPV) infection, having multiple sexual partners, indulging in receptive anal intercourse (anal sex), excessive smoking, medical history of vaginal, cervical or vulvar cancers. Moreover, immune-compromised patients who have a disease or condition which causes weakening of immune system such as organ transplant, human immunodeficiency virus (HIV), and others.
Market Dynamics
The increasing incidence of anal cancer and sexually transmitted diseases, rising research and development activities for the development of novel therapeutics for the treatment of anal cancer, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global anal cancer market over the forecast period.
For instance, according to data provided by the Cancer Research U.K. in 2018, around 1,500 new cases of anal cancer are reported every year in the U.K, i.e. four new anal cancer cases daily. The same source also states that the incidence rate of anal cancer in the U.K. is highest in elderly people of age 90 and above.
Key features of the study:
- This report provides in-depth analysis of the global anal cancer market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anal cancer market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global anal cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anal cancer market
Detailed Segmentation:
- Global Anal Cancer Market, By Drug Type:
- Fluorouracil
- Cisplatin
- Carboplatin
- Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
- Global Anal Cancer Market, By Cancer Type:
- Carcinoma In-situ
- Squamous Cell Carcinoma
- Melanoma
- Adenocarcinoma
- Basal Cell Carcinoma
- Global Anal Cancer Market, By Treatment Type:
- Chemotherapy
- Surgery
- Radiation Therapy
- Immunotherapy
- Global Anal Cancer Market, By Distribution Channel:
- Hospitals & Clinics
- Research & Academic Institutes
- Long-term Care Centers
- Pharmacies
- Global Anal Cancer Market, By Region:
- North America
- By Drug Type
- Fluorouracil
- Cisplatin
- Carboplatin
- Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
- By Cancer Type
- Carcinoma In-situ
- Squamous Cell Carcinoma
- Melanoma
- Adenocarcinoma
- Basal Cell Carcinoma
- By Treatment Type
- Chemotherapy
- Surgery
- Radiation Therapy
- Immunotherapy
- By Distribution Channel
- Hospitals & Clinics
- Research & Academic Institutes
- Long-term Care Centers
- Pharmacies
- By Country
- Latin America
- By Drug Type
- Fluorouracil
- Cisplatin
- Carboplatin
- Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
- By Cancer Type
- Carcinoma In-situ
- Squamous Cell Carcinoma
- Melanoma
- Adenocarcinoma
- Basal Cell Carcinoma
- By Treatment Type
- Chemotherapy
- Surgery
- Radiation Therapy
- Immunotherapy
- By Distribution Channel
- Hospitals & Clinics
- Research & Academic Institutes
- Long-term Care Centers
- Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type
- Fluorouracil
- Cisplatin
- Carboplatin
- Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
- By Cancer Type
- Carcinoma In-situ
- Squamous Cell Carcinoma
- Melanoma
- Adenocarcinoma
- Basal Cell Carcinoma
- By Treatment Type
- Chemotherapy
- Surgery
- Radiation Therapy
- Immunotherapy
- By Distribution Channel
- Hospitals & Clinics
- Research & Academic Institutes
- Long-term Care Centers
- Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type
- Fluorouracil
- Cisplatin
- Carboplatin
- Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
- By Cancer Type
- Carcinoma In-situ
- Squamous Cell Carcinoma
- Melanoma
- Adenocarcinoma
- Basal Cell Carcinoma
- By Treatment Type
- Chemotherapy
- Surgery
- Radiation Therapy
- Immunotherapy
- By Distribution Channel
- Hospitals & Clinics
- Research & Academic Institutes
- Long-term Care Centers
- Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Type
- Fluorouracil
- Cisplatin
- Carboplatin
- Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
- By Cancer Type
- Carcinoma In-situ
- Squamous Cell Carcinoma
- Melanoma
- Adenocarcinoma
- Basal Cell Carcinoma
- By Treatment Type
- Chemotherapy
- Surgery
- Radiation Therapy
- Immunotherapy
- By Distribution Channel
- Hospitals & Clinics
- Research & Academic Institutes
- Long-term Care Centers
- Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type
- Fluorouracil
- Cisplatin
- Carboplatin
- Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
- By Cancer Type
- Carcinoma In-situ
- Squamous Cell Carcinoma
- Melanoma
- Adenocarcinoma
- Basal Cell Carcinoma
- By Treatment Type
- Chemotherapy
- Surgery
- Radiation Therapy
- Immunotherapy
- By Distribution Channel
- Hospitals & Clinics
- Research & Academic Institutes
- Long-term Care Centers
- Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Advaxis, Inc.*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- ORYX GmbH and Co. KG
- Eli Lilly and Company
- Merck KGaA
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Onconova Therapeutics
- BioMimetix JV, LLC
- Bayer AG
- Spectrum Pharmaceuticals Inc.
- Global BioPharma Inc.
- Amgen Inc.
- Atara Biotherapeutics Inc.
- ISA Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Ono Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- Novartis AG
- Pfizer Inc.
- Sanofi
- Johnson & Johnson Private Limited
“*” marked represents similar segmentation in other categories in the respective section.
